These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18382694)

  • 1. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
    van Baarsen LG; Vosslamber S; Tijssen M; Baggen JM; van der Voort LF; Killestein J; van der Pouw Kraan TC; Polman CH; Verweij CL
    PLoS One; 2008 Apr; 3(4):e1927. PubMed ID: 18382694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.
    Vosslamber S; van der Voort LF; van den Elskamp IJ; Heijmans R; Aubin C; Uitdehaag BM; Crusius JB; van der Pouw Kraan TC; Comabella M; Montalban X; Hafler DA; De Jager PL; Killestein J; Polman CH; Verweij CL
    Genes Immun; 2011 Sep; 12(6):466-72. PubMed ID: 21471993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aligned Expression of IFI16 and STING Genes in RRMS Patients' Blood.
    Helbi S; Ravanbakhsh B; Karimi M; Kooti W; Jivad N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(6):878-886. PubMed ID: 31362682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
    Hecker M; Thamilarasan M; Koczan D; Schröder I; Flechtner K; Freiesleben S; Füllen G; Thiesen HJ; Zettl UK
    Int J Mol Sci; 2013 Aug; 14(8):16087-110. PubMed ID: 23921681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis.
    Charbit H; Benis A; Geyshis B; Karussis D; Petrou P; Vaknin-Dembinsky A; Lavon I
    J Clin Neurosci; 2015 Jun; 22(6):986-9. PubMed ID: 25882258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis.
    Satoh J; Nanri Y; Tabunoki H; Yamamura T
    BMC Neurol; 2006 May; 6():18. PubMed ID: 16709257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole genome analysis of the action of interferon-beta.
    Kauffman MA; Yankilevich P; Barrero P; Bello R; Marangunich L; Vidal A; Criscuolo M; Diez RA; Sterin Prync A
    Int J Clin Pharmacol Ther; 2009 May; 47(5):328-57. PubMed ID: 19473595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.
    Oturai DB; Søndergaard HB; Börnsen L; Sellebjerg F; Christensen JR
    Scand J Immunol; 2016 Jan; 83(1):72-80. PubMed ID: 26395032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-interferon exposure and onset of secondary progressive multiple sclerosis.
    Zhang T; Shirani A; Zhao Y; Karim ME; Gustafson P; Petkau J; Evans C; Kingwell E; van der Kop M; Zhu F; Oger J; Tremlett H;
    Eur J Neurol; 2015 Jun; 22(6):990-1000. PubMed ID: 25846809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
    Dabbaghi R; Safaralizadeh R; Rahmani S; Barpour N; Hosseinpourfeizi M; Rajabi A; Baradaran B
    BMC Res Notes; 2023 Oct; 16(1):273. PubMed ID: 37845751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
    Goertsches RH; Hecker M; Koczan D; Serrano-Fernandez P; Moeller S; Thiesen HJ; Zettl UK
    Pharmacogenomics; 2010 Feb; 11(2):147-61. PubMed ID: 20136355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta.
    Martínez-Aguilar L; Pérez-Ramírez C; Maldonado-Montoro MDM; Carrasco-Campos MI; Membrive-Jiménez C; Martínez-Martínez F; García-Collado C; Calleja-Hernández MÁ; Ramírez-Tortosa MC; Jiménez-Morales A
    Mutat Res Rev Mutat Res; 2020; 785():108322. PubMed ID: 32800273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OAS1: a multiple sclerosis susceptibility gene that influences disease severity.
    O'Brien M; Lonergan R; Costelloe L; O'Rourke K; Fletcher JM; Kinsella K; Sweeney C; Antonelli G; Mills KH; O'Farrelly C; Hutchinson M; Tubridy N
    Neurology; 2010 Aug; 75(5):411-8. PubMed ID: 20679634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.